Protection of Mice Against Syngeneic Lymphomata: II. Collaboration Between Drugs and Antibodies

Rabbit anti-mouse tumour cell serum can be made tumour specific by absorption with normal mouse cells and in an in vivo protection test can be shown to have a measurable protective effect on mice against a given number of lethal doses of a lymphoma. Some drugs have been evaluated in this system. Whe...

Full description

Saved in:
Bibliographic Details
Published in:British journal of cancer 1974-10, Vol.30 (4), p.305-311
Main Authors: Davies, D A L, Buckham, S, Manstone, A J
Format: Article
Language:English
Subjects:
Animals
Antibodies, Neoplasm - administration & dosage
Antineoplastic Agents - therapeutic use
Biomedical and Life Sciences
Biomedicine
Cancer Research
Carcinoembryonic Antigen
Cell Line
Chlorambucil - therapeutic use
Cyclophosphamide - therapeutic use
Drug Resistance
Epidemiology
Immunization, Passive
Immunodiffusion
Lymphoma - drug therapy
Lymphoma - immunology
Lymphoma - prevention & control
Melphalan - therapeutic use
Mice
Mice, Inbred C57BL
Models, Biological
Molecular Medicine
Neoplasms, Experimental - immunology
Neoplasms, Experimental - prevention & control
Oncology
original-article
Rabbits - immunology
Time Factors
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Rabbit anti-mouse tumour cell serum can be made tumour specific by absorption with normal mouse cells and in an in vivo protection test can be shown to have a measurable protective effect on mice against a given number of lethal doses of a lymphoma. Some drugs have been evaluated in this system. When drug treatment is combined with antibody treatment much greater protection can be obtained than when the same amounts of drug or antibody are used alone. It is preferable to administer drug before antibody and with the combined schedule it is possible in the test model to protect all mice from tumour growth, even allowing the tumour up to 48 h “get-away” time before starting treatment.
ISSN:0007-0920
1532-1827
DOI:10.1038/bjc.1974.197